UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/918,039	07/30/2001	Yong Mi Choi-Sledeski	P24450-E US1	3370

7590 06/27/2005

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950

EXAMINER	
TRUONG, TAMTHOM NGO	
ART UNIT	**PAPER NUMBER**
1624	

DATE MAILED: 06/27/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/918,039	CHOI-SLEDESKI ET AL.	
	Examiner	Art Unit	
	Tamthom N. Truong	1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *07 April 2005*.

2a)☐ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *35-41* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) *35-41* are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Applicant's amendment of 4-07-05 has been considered. The election with traverse of Group 17 (or XVII) is acknowledged. Group 17 was indicated with further restriction previously. Therefore, Group 17 is further divided according to the different combination of substituents of the claimed formula.

Claims 1-34, and 42 are cancelled.

Claims 35-41 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

   Ar^1 is pyrrolo[**2,3-c**]pyridinyl;

   R_2 is SO_2-phenyl, or SO_2-naphthyl;

   In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

   classified in classes 514, 546, various subclasses depending on substituents.

2. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-c]pyridinyl;

R_2 is SO_2-(5-membered heteroaryl or heterocyclyl);

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

3. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-c]pyridinyl;

R_2 is SO_2-(6-membered heteroaryl)

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

4. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-c]pyridinyl;

R_2 is SO_2-quinolinyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

5. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-c]pyridinyl;

R_2 is SO_2-benzopyranyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

6. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[**2,3-b**]pyridinyl;

R_2 is SO_2-phenyl, or SO_2-naphthyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

7. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-b]pyridinyl;

R_2 is SO_2-(5-membered heteroaryl or heterocyclyl);

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

8. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-b]pyridinyl;

R_2 is SO_2-(6-membered heteroaryl)

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

9. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-b]pyridinyl;

R_2 is SO_2-quinolinyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

10. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[2,3-b]pyridinyl;

R_2 is SO_2-benzopyranyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

11. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[**3,2-c**]pyridinyl;

R_2 is SO_2-phenyl, or SO_2-naphthyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

12. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[3,2-c]pyridinyl;

R_2 is SO_2-(5-membered heteroaryl or heterocyclyl);

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

13. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[3,2-c]pyridinyl;

R_2 is SO_2-(6-membered heteroaryl)

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

14. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[3,2-c]pyridinyl;

R_2 is SO_2-quinolinyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

15. Claims 35-41 (in part) drawn a method of treatment using compounds of the claimed formula, and pharmaceutical composition thereof, wherein:

Ar^1 is pyrrolo[3,2-c]pyridinyl;

R_2 is SO_2-benzopyranyl;

In combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents;

classified in classes 514, 546, various subclasses depending on substituents.

16. Claims 35-41 (in part) drawn a method of treatment using the remaining compounds of the claimed formula, and pharmaceutical composition thereof, wherein the combination of Ar^1 and R_2 is not in the above groups, in combination with at least one other agent selected from diagnostic agents, cardioprotective agents, direct thrombin inhibiting agents, anticoagulant agents, antiplatelet agents and fibrinoloytic agents; classified in classes 514, 546, various subclasses depending on substituents. Further restriction will be required if this group is elected.

The inventions are distinct, each from the other because of the following reasons:

a. Inventions groups 1-16 are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In

the instant case the combinations of rings represented by Ar^1, R_2 and the pyrrolidinone ring define the different inventions.

b. Athough all groups share the ring of *pyrrolidinone*, said ring alone does not sufficiently define the invention, and does not contribute to the art. Therefore, it is the combination of the *pyrrolidinone* with Ar^1 and R_2 that gives each group a distinct physical, chemical and/or biological properties, and thus sets apart the compounds of one group from those of the others. Thus, a reference that anticipated, or rendered obvious one group would not do so to the others, and so, a separate search is required for each group.

Because these inventions are distinct for the reasons given above and the search required for Group 1 is not required for Group 2-17, and the search for all 17 distinct invention would impose a serious burden upon the examiner in charge of this invention, restriction for examination purposes as indicated is proper.

Due to the complexity of the grouping, the restriction is presented in writing.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-F (10:00-6:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Tamthom N. Truong
Examiner
Art Unit 1624

JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

***
6-22-05